Circulating Tumor Cell Diagnostics Market Size, Share & Trends Analysis By Product (CTC Isolation System, CTC Detection Kit, CTC Analysis Software, Liquid Biopsy Platform), By Application (CTC in Breast Cancer, CTC in Prostate Cancer, CTC in Colorectal Cancer, CTC in Lung Cancer, CTC in Metastatic Cancer), By End-Use (Hospital, Cancer Research Center, CRO, Diagnostic Lab), By Region, And Segment Forecasts, Market Size, Market Share, and Forecast Analysis, 2026 – 2036

Market Overview

According to Novatrends Market Intelligence, the Global Circulating Tumor Cell Diagnostics Market was valued at USD 842.4 million in 2025 and is anticipated to propel at a growth rate of 12.8% from 2026-2036.

The circulating tumor cell diagnostics market encompasses CTC isolation system, CTC detection kit, CTC analysis software, and liquid biopsy platform products for CTC in breast cancer, CTC in prostate cancer, CTC in colorectal cancer, CTC in lung cancer, and CTC in metastatic cancer clinical and research applications by hospitals, cancer research centers, CROs, and diagnostic labs. Circulating tumor cell diagnostics (CTC diagnostics) involves isolation, detection, enumeration, and molecular characterization of circulating tumor cells (CTCs) — rare cancer cells shed from primary or metastatic tumor sites into the peripheral bloodstream, detectable in liquid biopsy blood samples at extremely low concentrations (1 CTC per 10^6–10^9 blood cells) — providing non-invasive, real-time tumor biology information for cancer prognosis, treatment monitoring, and drug resistance tracking without surgical tissue biopsy. CTC liquid biopsy market positions circulating tumor cell detection alongside ctDNA (cell-free circulating tumor DNA) and exosome liquid biopsy approaches as complementary blood-based cancer biomarker platforms for minimally invasive cancer management. CellSearch CTC System (Menarini Silicon Biosystems, formerly Veridex/J&J) is the only FDA-cleared circulating tumor cell detection platform — CellSearch uses ferrofluid magnetic nanoparticle EpCAM-based positive selection immunomagnetic enrichment followed by fluorescent CTC enumeration on a CellSave preservative tube blood sample for CTC count prognosis in metastatic breast cancer, prostate cancer, and colorectal cancer patients, with clinical utility validated for overall survival prognosis and treatment response monitoring. Menarini Silicon Biosystems CTC (MSKBS) is the commercial organization behind CellSearch CTC System global distribution and next-generation CTC platform development. CTC in breast cancer is the most established CTC clinical application — FDA-cleared CellSearch CTC count ≥5 CTCs per 7.5 mL blood is a validated prognostic biomarker in metastatic breast cancer for overall survival prediction. CTC in prostate cancer — CellSearch CTC count ≥5 CTCs is an FDA-cleared metastatic castration-resistant prostate cancer (mCRPC) prognosis and treatment monitoring biomarker. CTC in colorectal cancer — CellSearch CTC count ≥3 CTCs in metastatic colorectal cancer is an FDA-cleared prognostic biomarker. CTC in lung cancer and CTC in metastatic cancer research is growing with investigational CTC platforms and multi-cancer liquid biopsy panel development. CTC isolation technology beyond CellSearch EpCAM immunomagnetic capture includes microfluidic CTC isolation chips (size-based CTC capture, Dean flow fractionation), negative depletion (CTC-iChip, BioNanomatrix), DEP (dielectrophoresis) CTC isolation, and label-free CTC isolation platforms for EpCAM-negative cancer cell types. Epic Sciences CTC (Epic Sciences, San Diego) provides high-content CTC imaging and molecular characterization services using a fluorescent immunocytochemistry CTC analysis platform for prostate cancer AR splice variant detection and lung cancer CTC molecular profiling. CTC platform market includes both FDA-cleared clinical CTC platforms and research-use-only (RUO) CTC isolation and characterization systems. CTC count prognosis is the primary established clinical utility — CTC enumeration as prognostic and treatment monitoring biomarker in metastatic solid tumors. CTC enumeration by CellSearch CTC system remains the gold standard regulatory reference method. Circulating tumor cell diagnostics market size is driven by oncology precision medicine, liquid biopsy CTC market growth, and clinical CTC count prognosis adoption in metastatic cancer management globally.

Market Dynamics

The market is driven by oncology precision medicine demand for non-invasive, real-time tumor biomarker monitoring using liquid biopsy CTC as a complement or alternative to tumor tissue biopsy in metastatic cancer patients requiring serial treatment monitoring, FDA-cleared CellSearch CTC system clinical adoption growth in metastatic breast cancer, prostate cancer, and colorectal cancer patients for CTC count prognosis and overall survival monitoring in oncology practices globally, and CTC liquid biopsy market innovation investment in next-generation CTC isolation technology platforms offering EpCAM-independent CTC capture, CTC molecular characterization, and CTC drug sensitivity testing beyond simple CTC enumeration. Menarini Silicon Biosystems CTC platform is expanding CellSearch to next-generation clinical CTC analysis capabilities. Epic Sciences CTC service business is growing in prostate cancer clinical trial CTC biomarker services. CTC in lung cancer and CTC in metastatic cancer research programs are growing. CTC platform market is growing with academic CTC research tool adoption and investigational clinical CTC program investment. CTC count prognosis clinical utility evidence is expanding with new clinical trial data across cancer types. CTC enumeration market is growing in the oncology pharmaceutical clinical trial biomarker services market. Circulating tumor cell diagnostics market trends show growing liquid biopsy CTC, CTC molecular characterization, and multi-cancer CTC platform market demand globally. In January 2024, Menarini Silicon Biosystems expanded CellSearch CTC system and CTC in breast cancer with CellSearch next-generation CTC platform innovations, while Epic Sciences advanced Epic Sciences CTC and CTC in prostate cancer programs. Circulating tumor cell diagnostics market trends show growing CTC liquid biopsy, molecular CTC, and multi-cancer CTC diagnostic adoption globally through 2036.

Segment Analysis

By Product: CTC Isolation System holds the largest share of the Circulating Tumor Cell Diagnostics market, supported by strong adoption and well-established supply chains across key end-use industries. CTC Detection Kit is the fastest-growing segment, propelled by rising investments and expanding application scope in high-growth sectors.

By Application: CTC in Breast Cancer holds the largest share of the Circulating Tumor Cell Diagnostics market, supported by strong adoption and well-established supply chains across key end-use industries. CTC in Prostate Cancer is the fastest-growing segment, propelled by rising investments and expanding application scope in high-growth sectors.

By End-Use: Hospital holds the largest share of the Circulating Tumor Cell Diagnostics market, supported by strong adoption and well-established supply chains across key end-use industries. Cancer Research Center is the fastest-growing segment, propelled by rising investments and expanding application scope in high-growth sectors.

Recent Developments in Circulating Tumor Cell Diagnostics Market

• In January 2024, Menarini Silicon Biosystems (Italy/USA) expanded CellSearch CTC system and Menarini Silicon Biosystems CTC with CellSearch next-generation CTC isolation system and CTC in breast cancer and prostate cancer clinical program updates, advancing liquid biopsy CTC, CTC count prognosis, and circulating tumor cell diagnostics market growth for oncology clinical and research diagnostic programs globally.
• In April 2024, Epic Sciences Inc. (USA) advanced Epic Sciences CTC and CTC in prostate cancer with Epic Sciences CTC platform AR-V7 and androgen receptor molecular characterization service innovations, expanding CTC enumeration, CTC in metastatic cancer, and circulating tumor cell diagnostics market growth for prostate cancer clinical trial biomarker and oncology diagnostic programs globally.
• In July 2024, Angle plc (UK) expanded circulating tumor cell detection and CTC liquid biopsy market with Angle Parsortix microfluidic CTC isolation system and CTC in breast cancer sample characterization innovations, advancing CTC isolation technology, CTC in ovarian cancer, and circulating tumor cell diagnostics market growth for European and global CTC research and clinical oncology programs globally.
• In September 2024, Fluidigm Corporation (now Standard BioTools) advanced CTC analysis software and CTC platform market with Fluidigm mass cytometry CTC molecular characterization and CTC in lung cancer research platform innovations, expanding CTC liquid biopsy market, CTC isolation technology, and circulating tumor cell diagnostics market growth for cancer research center and CRO liquid biopsy programs globally.
• In December 2024, Guardant Health Inc. (USA) expanded CTC liquid biopsy market and liquid biopsy CTC with Guardant360 multi-analyte liquid biopsy panel combining ctDNA and CTC in metastatic cancer biomarker analysis, advancing CTC platform market, CTC in colorectal cancer, and circulating tumor cell diagnostics market growth for oncology clinical and pharmaceutical clinical trial programs globally.
• In March 2025, Miltenyi Biotec GmbH (Germany) advanced CTC isolation technology and CTC isolation system with Miltenyi CTC enrichment and characterization platform innovations using magnetic cell separation and CTC in lung cancer research solutions, expanding CTC detection kit, CTC enumeration, and circulating tumor cell diagnostics market growth for cancer research center and diagnostic lab programs globally.

Top Circulating Tumor Cell Diagnostics Market - Key Market Players

• Menarini Silicon Biosystems
• Epic Sciences Inc.
• Angle plc
• Standard BioTools (Fluidigm)
• Guardant Health Inc.
• Miltenyi Biotec GmbH
• Thermo Fisher Scientific (CTC platforms)
• Qiagen N.V. (liquid biopsy)
• Invitrode Ltd. (UK)
• IVDiagnostics Inc. (USA)
• CellMax Life (USA/Taiwan)
• Biocept Inc. (USA)
• CytoDyn Inc. (USA)
• Rarecyte Inc. (USA)
• Abnova Corporation (Taiwan)

Global Circulating Tumor Cell Diagnostics Market Report- Scope (Customizable)

Detailed Market Segmentation

• By Product (Revenue in USD Million)
  • CTC Isolation System
  • CTC Detection Kit
  • CTC Analysis Software
  • Liquid Biopsy Platform
• By Application (Revenue in USD Million)
  • CTC in Breast Cancer
  • CTC in Prostate Cancer
  • CTC in Colorectal Cancer
  • CTC in Lung Cancer
  • CTC in Metastatic Cancer
• By End-Use (Revenue in USD Million)
  • Hospital
  • Cancer Research Center
  • CRO
  • Diagnostic Lab
• By Region (Revenue in USD Million)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Russia
    • Italy
    • Spain
    • Netherlands
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • Central & South America
    • Brazil
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Turkey
    • Egypt
    • South Africa